SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients
Status:
Recruiting
Trial end date:
2023-10-22
Target enrollment:
Participant gender:
Summary
When gemcitabine based chemo and fluorouracil based chemo regimes are failed in late-stage or
recurrent pancreatic cancer patients, there is no alternative options. Anti-PD-1 antibody has
became a promising anti-cancer drug. While it showed limited efficacy in pancreatic cancer.
Stereotactic Body Radiotherapy has been a new method to locally treat metastatic cancer. This
study is aimed to evaluate the safety and efficacy of the combination of SBRT and anti-PD-1
antibody in late-stage or recurrent pancreatic caner who failed in second-line chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University